Histogenics announces plans to price initial public offering of stock

Cowen, Needham, Canaccord Genuity are joint bookrunners; BTIG assists

By Devika Patel

Knoxville, Tenn., Oct. 7 – Histogenics Corp. will conduct an initial public offering of its common stock with a 30-day greenshoe option, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

Cowen and Co., Needham & Co. and Canaccord Genuity are the joint bookrunning managers. BTIG is the co-manager.

Sofinnova Venture Partners, Split Rock Partners and Wilmslow Estates Ltd. may invest up to $15 million. Intrexon Corp. plans to invest $15 million.

Proceeds will be used to develop and advance NeoCart and to build out manufacturing facilities, as well as for working capital and general corporate purposes.

The regenerative medicine company is based in Waltham, Mass. It intends to list its common stock on the Nasdaq under the symbol “HSGX.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.